Lilly Set to Launch Lantus Biosimilar in the US Next Year

Eli Lilly and Sanofi have agreed terms in a patent dispute revolving around insulin glargine which will ward off the launch of a biosimilar to Sanofi’s Lantus brand until the end of next year.


Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept), a Biosimilar of Enbrel, in Korea (1)The settlement relates to patents covering Sanofi’s Lantus SoloSTAR formulation of the basal insulin, a pen injector version which accounts for almost two-thirds of Lantus $7bn total sales. It does not cover insulin glargine sold in vials or combination products.


iStock_000018443917_XXXLargeUnder the terms of the agreement Lilly has agreed to pay royalties to Sanofi in exchange for a patent license from Sanofi, and has agreed to hold off on launching its own pen-based insulin glargine product Basaglar – partnered with Boehringer Ingelheim – until December 15, 2016.


Read More